2.1 Univariate Analysis of Tetanus Patients Receiving ICU Treatment
Among the 34 patients, 18 (52.90%) were categorized into the ICU group, and 16 (47.10%) into the non-ICU group based on whether they received ICU treatment. There were no statistically significant differences between the two groups in terms of age, gender, underlying diseases, time from onset to medical treatment, total bilirubin, creatinine, creatine kinase, creatine kinase isoenzyme, and lymphocyte count (P>0.05). However, statistically significant differences were observed in white blood cell count, platelet count, neutrophil count, and the Systemic Immune Inflammation Index (SII) between the two groups (P<0.05). Refer to Table 1 for details.
Table 1: Univariate Analysis of Tetanus Patients Receiving ICU Treatment
Variable
|
ICU Group(n=18)
|
|
Non-ICU Group(n=16)
|
c2/ t Value
|
P Value
|
Gender[n(%)]
|
|
|
|
|
0.216
|
0.642
|
|
Male
|
11(61.11)
|
|
11(68.75)
|
|
|
|
Female
|
7(38.89)
|
|
5(31.25)
|
|
|
Underlying Diseases[n(%)]
|
|
|
|
|
2.862
|
0.091
|
|
Present
|
4(22.22)
|
|
8(50.00)
|
|
|
|
Absent
|
14(77.78)
|
|
8(50.00)
|
|
|
Age (years)
|
62.22±12.55
|
|
61.88±13.65
|
0.077
|
0.939
|
Time from Onset to Treatment (days)
|
2.78±1.66
|
|
3.88±3.59
|
-1.164
|
0.253
|
White Blood Cell Count(×109∕L)
|
10.00±3.14
|
|
6.55±1.99
|
3.776
|
0.001
|
Platelet Count(×109∕L)
|
284.28±81.61
|
|
219.13±68.19
|
2.508
|
0.017
|
Total Bilirubin(×109∕L)
|
15.33±5.36
|
|
16.37±9.54
|
-0.398
|
0.693
|
Creatinine(×109∕L)
|
62.39±11.88
|
|
63.94±11.11
|
-0.393
|
0.698
|
Creatine Kinase(×109∕L)
|
334.33±205.73
|
|
222.75±207.19
|
1.573
|
0.125
|
Creatine Kinase Isoenzyme(×109∕L)
|
21.11±10.77
|
|
18.50±16.33
|
0.556
|
0.582
|
Neutrophil Count(×109∕L)
|
8.16±3.36
|
|
4.27±1.84
|
4.114
|
<0.001
|
Lymphocyte Count(×109∕L)
|
1.45±0.78
|
|
1.61±0.58
|
-0.649
|
0.521
|
SII
|
2222.15±2197.33
|
|
624.84±349.71
|
3.041
|
0.007
|
2.2 Multivariate Analysis of Tetanus Patients Receiving ICU Treatment
Building upon the results of univariate analysis, variables with statistically significant differences, including white blood cell count, platelet count, neutrophil count, and the Systemic Immune Inflammation Index (SII), were selected as independent variables. Binary logistic regression analysis was conducted with the acceptance of ICU treatment as the dependent variable. The results indicated that SII is a risk factor for tetanus patients requiring ICU treatment. Refer to Table 2 for details.
Table 2: Multivariate Analysis of Tetanus Patients Receiving ICU Treatment
Variable
|
β
|
Wald
|
P Value
|
OR
|
95% C.I.for OR
|
Lower
|
Upper
|
SII
|
0.003
|
4.029
|
0.045
|
1.003
|
1.000
|
1.006
|
Neutrophil Count
|
0.673
|
3.399
|
0.065
|
1.961
|
0.958
|
4.010
|
Constant
|
-6.844
|
6.282
|
0.012
|
0.001
|
|
|
2.3 Predictive Value of SII for Tetanus Patients Receiving ICU Treatment
The SII demonstrated significant predictive value for tetanus patients requiring ICU treatment, with an area under the curve (AUC) of 0.896 (95% CI 0.790–1.000, P<0.001). At the optimal cutoff value of 892.98, the sensitivity of SII in predicting tetanus patients requiring ICU treatment was 83.3%, with a specificity of 87.5%. Refer to Figure 1 for the ROC curve illustrating the predictive performance of SII.
Figure 1: ROC Curve of SII for Predicting ICU Treatment in Tetanus Patients
2.4 Prognosis
The prognosis of tetanus patients varied based on the initial treatment location. Among those initially treated in the ICU, 6 patients were admitted, 5 were cured, and 1 patient opted for treatment discontinuation. For patients transferred from general wards to the ICU, 12 were admitted, 9 were cured, and 3 patients chose to discontinue treatment. One patient initially admitted to a general ward, who deteriorated but refused transfer to the ICU, opted for treatment discontinuation. All 15 patients continuously treated in general wards were cured. Refer to Table 3 for a comparison of the cure rates among different treatment groups.
Table 3: Comparison of Cure Rates in Different Initial Treatment Settings
Group
|
Total Number (cases)
|
Discontinuation/Death (cases)
|
Cured (cases)
|
Cure Rate (%)
|
First ICU Treatment
|
6
|
1/0
|
5
|
83.33
|
Transfer to ICU Treatment
|
12
|
3/0
|
9
|
75.00
|
Continuous General Ward Treatment
|
15
|
0/0
|
15
|
100.00
|
Total
|
33
|
4/0
|
29
|
87.88
|